The AI Now Institute, through its co-executive director Sarah Myers West, has raised concerns about the current methods for evaluating AI safety. West argues that the industry's reliance on general benchmarks is insufficient, advocating instead for evaluations that are specific to real-world use cases. She draws a parallel to medical drug testing, where safety is assessed for particular applications, dosages, and patient types, suggesting a similar approach is needed for AI. AI
IMPACT Highlights the need for more nuanced and use-case specific AI safety evaluations beyond general benchmarks.
RANK_REASON The item is an opinion piece from a policy research center director criticizing current industry practices.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
